Skip to main content
. 2016 Jan 25;5(4):263–270. doi: 10.1016/j.molmet.2016.01.007

Figure 3.

Figure 3

C57Bl/6 Insl5−/− mice have impaired hepatic glucose production. (A) Oral glucose tolerance test (OGTT) and (B) serum insulin levels after glucose gavage in 12 to 14-week-old C57Bl/6 WT and Insl5−/− mice (n = 7–24). (C) Intraperitoneal glucose tolerance test (IPGTT) and (D) serum insulin levels after glucose injection in Insl5−/− and C57Bl/6 WT mice (n = 10). (E) Insulin tolerance test (ITT) in Insl5−/− and C57Bl/6 WT mice (n = 7). (F) Pyruvate tolerance test (PTT) in Insl5−/− and C57Bl/6 WT mice (n = 9–10). (G) Immunoblot analysis of G6PC in liver tissue from Insl5−/−mice and C57Bl/6 WT mice after a 12 h fast (n = 8–9). (H) G6Pase activity in liver tissue from C57Bl/6 Insl5−/−mice and WT mice after a 12 h fast (n = 6–9). (I) Immunoblot analysis of PEPCK in liver tissue from C57Bl/6 Insl5−/−mice and WT mice after a 12 h fast (n = 8–9). (J) Glycogen levels in liver tissue from Insl5−/−mice and C57Bl/6 WT mice after a 6 and 12 h fast (n = 6–9). Data are mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.

HHS Vulnerability Disclosure